Posted by Michael Wonder on 04 Nov 2021
UNION therapeutics receives FDA fast track designation for oral orismilast for the treatment of moderate to severe atopic dermatitis
4 November 2021 - FDA's fast track designation for oral orismilast underscores the urgent need for new treatment option with potential to fulfil the unmet medical needs for people affected by atopic dermatitis.
UNION therapeutics today announced that the US FDA has granted fast track designation to oral orismilast for the treatment of moderate to severe atopic dermatitis.
